Russell Medford

Russell, a Managing Partner of The Salutramed Group, is a senior biotechnology executive with extensive private and public company experience as Chief Executive Officer and Board member of multiple biotechnology and health-related companies and organizations. From 1995 to 2009, he was co-founder, President, CEO, and Director of publicly-held AtheroGenics, Inc. and was a founding Board Director of publicly-held Inhibitex, Inc. (Nasdaq: INHX) until it was acquired by Bristol-Myers-Squibb in 2012 for $2.5 billion. He has extensive experience in financial markets including IPOs raising over $500 million for corporate, clinical development, and research programs.